CluePoints Brand Evolution Confirms Commitment to ‘Turning Artificial Intelligence into Human Intelligence’
June 11, 2024 – Clinical Trials, Other, Pharmaceutical – CluePoints, artificial intelligence, machine learning, statistical analysis
CluePoints extends its use of AI/ML and continues to find smarter ways to manage clinical trials
11 June 2024 — Pennsylvania, US — CluePoints, provider of leading statistical and AI-driven software solutions, today unveiled the evolution of its brand through the launch of a new website. The brand evolution represents the breadth and depth of CluePoints’ product innovation as it further invests in providing clients with the highest quality data review software. CluePoints aims to make clinical trials more efficient through harnessing Artificial Intelligence (AI) to facilitate critical thinking and focus on what matters most, aligning with the company vision for the future.
Explaining the new developments, CluePoints CEO Andy Cooper said: “CluePoints’ brand evolution is an important marker as we continue to innovate and grow our product suite and leverage the potential of AI and Machine Learning (ML) to enable the highest quality clinical research outcomes. We now provide a smarter way of detecting and managing risks that may impact the outcome of clinical trials and we understand the weight of responsibility that comes with our expertise. Every algorithm, every insight, is a conduit for delivering real, tangible benefits to our customers, to iCROs, and to patients around the world.
It’s not merely about technology for technology’s sake; it’s about leveraging these tools to reshape the landscape of clinical trials, turning AI into human intelligence. It’s not just a slogan or abstract concept; it reflects our commitment to improving research through better data interrogation and review which is the essence of the CluePoints brand. And by aligning talented people, the right processes and supporting customers to optimise their outcomes, we can continue to help our clients to develop innovative therapies that benefit people’s lives globally.”
The refreshed brand narrative defines how CluePoints turns AI into human intelligence:
- By providing high quality, reliable data that sponsors & CROs can trust
- By using a unique combination of advanced statistics, language models and other deep learning models to create intelligent solutions for smarter trials
- By driving meaningful change to accelerate clinical development
- By streamlining the day-to-day workload of sponsors and CROs
- By simplifying operational processes
- By building confident, smarter decision making into the clinical trials eco-system.
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of AI using advanced statistics and ML to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA and ICH E6 (R2), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM. Visit: www.cluepoints.com.
